Abstract

Mental health research has fallen behind other areas of medicine and the current trial-and-error approach of treating depression takes time, often without success. There is an urgent need for innovation in mental health and the development of effective treatment options.

Psychedelic therapy has drawn a lot of interest in recent years due to significant research advances for the treatment of various mental health conditions. This includes research of COMP360 psilocybin therapy, COMPASS Pathways’ proprietary synthesised formulation of psilocybin, which is currently undergoing phase 3 investigation in treatment-resistant depression. At COMPASS, we want to find better ways to support people living with mental health challenges, which is why we’re combining our innovative therapies with psychological support and next-generation digital tools and technologies to forge new, sustainable mental health care pathways. With those capabilities playing a role, we are paving the way to a more personalised, predictive, and preventative care.

With the rising potential for psychedelic treatments, such as COMP360, to enter the clinical setting, foresight is needed into how these therapies are integrated into wider health systems. We want to bring these innovations to patients as quickly as possible, but in a way that prioritises safety, efficacy, quality, and accessibility. This is why our clinical studies have been designed to ensure that they address the right questions for regulators, payors and insurers, so that COMP360 can be integrated into health systems, and supported by payors, if approved in future.

We are determined to build the future of mental health care for patients living with often invisible, yet profoundly debilitating conditions. A clinical and cultural shift in mental health care is essential to help millions of individuals—and their friends and families—who are affected.